Tradegate
31.10.25 | 16:43
38,720 Euro
+0,73 % +0,280
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 38,140 | 38,540 | 02.11. | |
| 38,160 | 38,720 | 31.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.10. | Medincell to Participate in the 2025 Truist Securities Biopharma Symposium (New-York) | 202 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will speak on Medincell's value proposition, including recent developments and meet with investors... ► Artikel lesen | |
| 13.10. | FDA approves Teva and Medincell's bipolar I disorder treatment | 27 | Pharmaceutical Technology | ||
| 10.10. | Medincell: FDA Approves Expanded Indication for UZEDY (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder | 344 | Business Wire | FDA approves UZEDY (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar... ► Artikel lesen | |
| MEDINCELL Aktie jetzt für 0€ handeln | |||||
| 23.09. | Teva and Medincell's Risperidone LAI Approved in Canada as LONGAVO | 452 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Teva Canada Limited, a subsidiary of Medincell's partner Teva Pharmaceutical Industries Ltd., has received regulatory approval for risperidone LAI... ► Artikel lesen | |
| 22.09. | Medincell Reports Positive Phase 3 Safety Data For Olanzapine LAI; No PDSS Observed | 315 | AFX News | PETAH TIKVA (dpa-AFX) - Medincell SA (MEDCL.PA) reported that new long-term safety data from the completed Phase 3 SOLARIS trial support the potential of Olanzapine LAI (TEV-749) as the first... ► Artikel lesen | |
| 22.09. | Medincell: New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile - No PDSS Observed | 323 | Business Wire | There were no suspected or confirmed PDSS (Post-injection Delirium/Sedation Syndrome)1 events observed with Medincell's Olanzapine LAI through week 56 in the pivotal Phase 3 SOLARIS trial2 The... ► Artikel lesen | |
| 22.09. | Medincell: New Data Show that UZEDY Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna | 307 | Business Wire | UZEDY was associated with a 2.89-day shorter length of hospital stay compared with Invega Sustenna (paliperidone palmitate) This translates to estimated direct cost savings of $3200 per hospitalization... ► Artikel lesen | |
| 17.09. | Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation | 480 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Data from the completed phase 3 SOLARIS trial to be presented at the 2025 Psych Congress Annual Meeting, taking place from September 17 21, 2025,... ► Artikel lesen | |
| 12.09. | Medincell Appoints Three New Members to Board of Directors | 2 | Contract Pharma | ||
| 12.09. | Medincell appoints three biotech veterans to board of directors | 1 | Investing.com | ||
| 12.09. | Medincell Announces the Appointment of Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to Its Board of Directors | 497 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL) General Assembly held on September 11, 2025, has approved the appointments of three new independent board members: Dr Sharon Mates, Dr. Charles Kunsch,... ► Artikel lesen | |
| 10.09. | Medincell: UZEDY Approved in South Korea Following Successful US Launch | 370 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Teva Handok announced today that UZEDY, Long-Acting Injectable Risperidone for Schizophrenia, has received regulatory approval from the South Korean... ► Artikel lesen | |
| 05.09. | Medincell to Present at the H.C. Wainwright 27th Global Investment Conference and Participate in the Morgan Stanley 23rd Global Healthcare Conference | 472 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Christophe Douat, Chief Executive Officer, will participate along with Dr Grace Kim, Chief Strategy Officer, U.S. Finance, in the following September... ► Artikel lesen | |
| 03.09. | Medincell: Reminder of the Participation Terms in the Combined General Meeting | 439 | Business Wire | Regulatory News:
The Annual General Meeting and Extraordinary General Meeting will be held at Medincell's (Paris:MEDCL) headquarters (3 rue des Frères Lumière, 34830 Jacou, France) on Thursday... ► Artikel lesen | |
| 04.08. | Medincell: Notice of the 2025 Annual General Meeting Published | 562 | Business Wire | Regulatory News:
Medincell's (Paris:MEDCL) combined annual general meeting (ordinary and extraordinary) will be held on September 11, 2025, at 6pm at the Company's headquarters. The notice... ► Artikel lesen | |
| 30.07. | Medincell: UZEDY Accelerates: 2025 Revenue Outlook Raised to $190-$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025 | 590 | Business Wire | Regulatory News:
Medincell's (Paris:MEDCL) partner Teva Pharmaceuticals shared today the following information:
About UZEDY
1-Month and 2-Month subcutaneous risperidone for schizophrenia
Commercialized... ► Artikel lesen | |
| 30.07. | Medincell Announces the Availability of its 2024-25 Universal Registration Document including the Annual Financial and CSR Reports | 542 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
The 2024-25 Universal Registration Document (URD) filed with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference... ► Artikel lesen | |
| 29.07. | Medincell Proposes Board Appointments of Industry Veterans Dr. Sharon Mates and Dr. Charles Kunsch | 655 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Sharon Mates, PhD, is the co-founder and former Chair and CEO of Intra-Cellular Therapies, a CNS-focused biotech that developed the successful... ► Artikel lesen | |
| 24.07. | Medincell: Half-Year Liquidity Contract Statement | 492 | Business Wire | Regulatory News:
Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2025:... ► Artikel lesen | |
| 17.06. | Medincell Publishes its Consolidated Annual Financial Results | 600 | Business Wire | (April 1st, 2024 March 31st, 2025) Consolidated financial statements for the year 2024-25 (IFRS standards) Revenues: €25.4 million, multiplied by 2.8x compared to previous year
? Other... ► Artikel lesen |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,40 | +0,22 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| EVOTEC | 7,054 | -0,59 % | EQS-News: Evotec SE: Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
27.10.2025 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| MEDIGENE | 0,052 | -3,36 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| QIAGEN | 40,760 | +0,90 % | Dax lässt nach - Merck und Qiagen gefragt | Frankfurt/Main - Zum Wochenausklang hat der Dax nachgelassen. Zum Xetra-Handelsschluss wurde der Index mit 23.958 Punkten berechnet, ein Minus in Höhe von 0,7 Prozent im Vergleich zum Vortagesschluss.... ► Artikel lesen | |
| CUREVAC | 4,600 | -0,48 % | BionTech Aktie startet Übernahme von CureVac - Jetzt Aktien kaufen? | ||
| MODERNA | 23,620 | -1,11 % | Watch Cigna, Moderna, Reddit, and More | ||
| VALNEVA | 4,012 | -0,20 % | Valneva-Aktie sorgt für Unruhe - Analysten warnen vor einem möglichen Schockstart in die Woche! | ||
| AMGEN | 258,00 | +0,12 % | Amgen Announces 2025 Fourth Quarter Dividend | THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the... ► Artikel lesen | |
| NOVAVAX | 7,227 | -0,92 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| STRYKER | 308,30 | -0,29 % | Stryker Corp. Q3 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - Stryker Corp. (SYK) revealed earnings for its third quarter that Increased from the same period last year and beat the Street estimates.The company's earnings came in... ► Artikel lesen | |
| BIOGEN | 134,45 | +0,37 % | Ihre wichtigsten Termine: Apple, Mastercard, Eli Lilly, Biogen, VW, Wacker Chemie und Lufthansa im Fokus! | © Foto: Jonathan Brady/PA Wire/dpa +++ dpa-Bildfunk Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine... ► Artikel lesen | |
| BIOFRONTERA | 2,780 | +3,73 % | Biofrontera trennt sich vom US-Geschäft | Das Leverkusener Biopharma-Unternehmen hat seine amerikanischen Aktivitäten verkauft. Die Transaktion soll Kosten senken und Risiken eliminieren. Doch was bleibt übrig? Klarer Schnitt mit Folgen: Die... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,920 | -2,34 % | Heidelberg Pharma erhält Rückenwind von der FDA | Die US-Zulassungsbehörde macht Tempo. Heidelberg Pharma (ISIN DE000A11QVV0) hat für seinen Wirkstoffkandidaten HDP-101 den Fast-Track-Status von der FDA erhalten. Das ist mehr als nur ein bürokratischer... ► Artikel lesen | |
| ILLUMINA | 107,18 | -0,24 % | Illumina, Inc.: Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025 | Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basis
GAAP operating margin of 21.0% and non-GAAP operating... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 69,80 | +0,17 % | Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen | DJ Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen
Von Dylan Tokar und Peter Loftus
DOW JONES--Novartis will den US-Biotech-Konzern Avidity Biosciences für 12 Milliarden... ► Artikel lesen |
MEDINCELL SA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,73 % bei einem Aktienkurs von 38,720 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDINCELL SA finden Sie auf Wallstreet Online.